Pretax income is the income that a company earns before paying income taxes. UroGen Pharma's pretax income for the
three
months ended in Dec. 2024 was $-34.86 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-124.04 Mil.
UroGen Pharma's pretax margin was -141.92%.
During the past 10 years, UroGen Pharma's highest Pretax Margin was -11.07%. The lowest was -584144.44%. And the median was -227.66%.
UroGen Pharma Pre-Tax Income Historical Data
The historical data trend for UroGen Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of UroGen Pharma's Pre-Tax Income
For the Biotechnology subindustry, UroGen Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-124.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (NAS:URGN) Pre-Tax Income Explanation
UroGen Pharma's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 10 years, UroGen Pharma's highest Pretax Margin was -11.07%. The lowest was -584144.44%. And the median was -227.66%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your 